Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-30, Stock:NVS, The news for the past five days is as follows:
2018-01-23: NEWS1: Key Updates on Novartis’s Kymriah.NEWS2: Analysts More Bullish On Celgene-Juno, But Sales Outlook Nags.NEWS3: Novartis Announces Positive Results on Migraine Candidate.NEWS4: VTVT Up 30% In 5 Days, INO Gets Shot In The Arm, DRNA, HBIO On Fire.NEWS5: VTVT Up 30% In 5 Days, INO Gets Shot In The Arm, DRNA, HBIO On Fire.NEWS6: Pre-Market Earnings Report for January 24, 2018 :  CMCSA, GE, UTX, ABT, GD, ITW, NSC, TEL, PGR, NVS, APH, RCL.NEWS7: 3 Pharma and Biotech Stocks to Watch Out for in 2018.NEWS8: How Is Novartis’s Kymriah Positioned for 2018?.NEWS9: Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb.NEWS10: 3 Pharma and Biotech Stocks to Watch Out for in 2018.NEWS11: Novartis on the Street: Analyst Ratings and Recommendations.NEWS12: Celgene, Novartis Both Report Billion Dollar Buyouts.NEWS13: The Top 5 Johnson & Johnson Shareholders (JNJ).NEWS14: Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies.NEWS15: Why Celgene's Acquisition Of Juno Matters For Biotech And Investors.NEWS16: Reading the Estimates for Novartis’s Alcon in 4Q17.NEWS17: What’s Expected of Novartis’s Sandoz Segment in 4Q17?.NEWS18: The Swiss Stock Market Climbed On Strength Of Index Heavyweights.NEWS19: The Swiss Stock Market Climbed On Strength Of Index Heavyweights.NEWS20: Teva Pharmaceutical Industries Ltd -- Moody's: European generic drug market growth to continue into 2020 on patent expiries, rising usage.
2018-01-24: NEWS1: Spark licenses blindness gene therapy rights outside U.S. to Novartis.NEWS2: Novartis AG (NVS) Q4 2017 Earnings Conference Call Transcript.NEWS3: Why Valeant's 162% Climb Over Nine Months 'Makes No Sense'.NEWS4: Novartis Tops A High After Crushing Fourth-Quarter Expectations.NEWS5: Behind Celgene’s Strategy in the Juno Therapeutics Acquisition.NEWS6: Novartis AG (NVS) Q4 2017 Earnings Conference Call Transcript.NEWS7: How Juno Therapeutics’ Cellular Immunotherapy Portfolio Could Help Celgene.NEWS8: Novartis Reaches Licensing, Supply Agreement With Spark For LUXTURNA Outside US.NEWS9: Novartis Reaches Licensing, Supply Agreement With Spark For LUXTURNA Outside US.NEWS10: Novartis Climbs Out of Its Growth Pit.NEWS11: European ADRs Move Higher in Wednesday Trading.NEWS12: How Is Novartis’s Cosentyx Positioned for 2018?.NEWS13: Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto.NEWS14: Novartis says Entresto could become $5 billion a year blockbuster drug.NEWS15: How Is Kisqali Positioned for 2018?.NEWS16: Novartis poised for growth as CEO hands baton to U.S. newcomer.NEWS17: Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto.NEWS18: Novartis’s Crizanlizumab Demonstrates Positive Results in Trials.NEWS19: The Swiss Stock Market Dipped Despite Novartis Strength.NEWS20: The Swiss Stock Market Dipped Despite Novartis Strength.NEWS21: European Markets Dropped As Euro And Pound Rally.NEWS22: European Markets Dropped As Euro And Pound Rally.NEWS23: Novartis beats 4Q profit forecasts.NEWS24: [$$] Novartis 4Q Profit Rises, Buoyed by Sales of New Drugs.NEWS25: Wall Street Poised For An Initial Climb.NEWS26: Wall Street Poised For An Initial Climb.NEWS27: Novartis Sees Return to Growth This Year With New Chief.NEWS28: European Shares Fall As Dollar Rout Deepens.NEWS29: European Shares Fall As Dollar Rout Deepens.NEWS30: Novartis Q4 Profit Surges, Above Estimates; Sees Growth In FY18; Stock Up.NEWS31: Novartis Q4 Profit Surges, Above Estimates; Sees Growth In FY18; Stock Up.NEWS32: Novartis Q4 Profit Surges, Tops Estimates, Lifts Dividend; Sees Growth In FY18.NEWS33: Novartis Q4 Profit Surges, Tops Estimates, Lifts Dividend; Sees Growth In FY18.NEWS34: Novartis Announces Positive Results on Migraine Candidate.
2018-01-25: NEWS1: GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017.NEWS2: Biogen Revenue Tops As Spinraza, MS Drugs Deliver Upside.NEWS3: Biogen Revenue Tops As Spinraza, MS Drugs Deliver Upside.NEWS4: Celgene Reverses In Fourth Quarter As Otezla Sales Rebound.NEWS5: Celgene Reverses In Fourth Quarter As Otezla Sales Rebound.NEWS6: What Analysts Recommend for GlaxoSmithKline in January 2018.NEWS7: Taking Stock of Radius Health’s Licensing Agreements.NEWS8: Trump speaks with leaders from Total, Novartis and others....NEWS9: A Strong Pipeline of Drugs Bodes Well for Radius Health.NEWS10: European ADRs Move Higher in Thursday Trading.NEWS11: European ADRs Move Higher in Thursday Trading.NEWS12: Analysts’ Ratings for Radius Health and Its Peers in January.NEWS13: How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?.NEWS14: Analysts’ Estimates for Pfizer’s 4Q17 Earnings.NEWS15: Tasigna Could Boost Novartis’s Revenue Growth in 2018.NEWS16: Novartis Receives 2 Breakthrough Therapy Designations in January.NEWS17: The Swiss Stock Market Pulled Back After ECB Announcement.NEWS18: The Swiss Stock Market Pulled Back After ECB Announcement.NEWS19: Spark licenses blindness gene therapy rights outside U.S. to Novartis.
2018-01-26: NEWS1: Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors.NEWS2: Stocks With Rising Relative Strength: Novartis.NEWS3: Stocks With Rising Relative Strength: Novartis.NEWS4: Novartis Gets Spark Therapeutics' Luxterna License Outside US.NEWS5: Novartis Gets Spark Therapeutics' Luxterna License Outside US.NEWS6: Anoro Ellipta May Boost GlaxoSmithKline’s Respiratory Franchise Revenues.NEWS7: Novartis Gets Spark Therapeutics&apos; Luxterna License Outside US.NEWS8: GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment.NEWS9: What to Expect for Novartis’s Subsidiary Alcon in 2018.NEWS10: GlaxoSmithKline Has Developed a Broad Respiratory Portfolio.NEWS11: Taking Stock of Radius Health’s Financial Performance.NEWS12: How Is Novartis’s Subsidiary Sandoz Positioned for 2018?.NEWS13: The Swiss Stock Market Recovered Some Lost Ground.NEWS14: The Swiss Stock Market Recovered Some Lost Ground.
2018-01-29: NEWS1: Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors.NEWS2: Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors.NEWS3: Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion.NEWS4: Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion.NEWS5: Novartis&apos; Lutathera Gets FDA Approval for Pancreatic Tumors.NEWS6: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS7: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS8: Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ.NEWS9: Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ.NEWS10: Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ.NEWS11: The Swiss Stock Market Pulled Back As Investors Turn Cautious.NEWS12: The Swiss Stock Market Pulled Back As Investors Turn Cautious.

Answer: Decrease